MOMasaki Ohyagi

Masaki Ohyagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaki Ohyagi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Akihiko Yoshimura

    Division of Molecular Pathology, Research Institute for Biomedical Sciences, Tokyo Uiversity of Science, Noda, Chiba, 278-0022, Japan

    5 shared publications
  • Takanori Yokota

    Department of Neurology and Neurological Science Institute of Science Tokyo Tokyo Japan

    5 shared publications
  • Kie Yoshida-Tanaka

    Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519 Tokyo

    4 shared publications
  • Tetsuya Nagata

    Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519 Tokyo

    4 shared publications
  • Kensuke Ihara

    Department of Cardiovascular Medicine Institute of Science Tokyo Tokyo Japan

    3 shared publications
  • Satoe Ebihara

    Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519 Tokyo

    3 shared publications

Latest Publications

  • Open Access

    Senescence of T cells and organ aging

    by Masaki Ohyagi, Minako Ito, Akihiko Yoshimura

    Senescence of T cells is strongly linked to organismal aging through two interconnected processes: chronic low-grade inflammation and reduced immune surveillance of senescent cells. T cells are particularly vulnerable to thymic involution, hematopoietic stem cell aging, repeated homeostatic proliferation, chronic antigenic stimulation, and metabolic and mitochondrial dysfunction. As a result, aged T cells may lose their capacity to combat infection and eliminate senescent cells, while also contributing to inflammaging through the production of inflammatory cytokines. Recent preclinical studies in murine models have demonstrated that modulation of T-cell immunosenescence can ameliorate age-related diseases. These approaches include PD-1/PD-L1 blockade, senolytic chimeric antigen receptor T (CAR-T) cells, and CXCL4/platelet factor 4 (PF4). In addition, early-stage human clinical studies of caloric restriction, low-dose mTOR inhibition, thymic regeneration, and mesenchymal stromal/stem cell (MSC) therapy suggest that interventions targeting immunosenescence may provide health benefits. Moreover, in murine models of Alzheimer’s disease, T cells infiltrating the brain may exert either disease-promoting or protective effects depending on the disease stage, highlighting an important point of intersection between T-cell-mediated immunosenescence and brain aging. This review summarizes the basic concepts of immunosenescence, the molecular basis of immune surveillance of senescent cells, age-associated T-cell subsets, their links to brain aging, and interventional strategies aimed at clinical translation, with particular emphasis on T-cell biology and the transcriptional regulatory network driven by NR4a.


  • Open Access

    Heteroduplex oligonucleotide technology boosts gene knockdown in cardiac and skeletal muscles

    by Sakino Matsuda-Kawabata, Tetsuya Nagata, Mitsugu Yanagidaira, Kensuke Ihara, Masaki Ohyagi, Hidetoshi Kaburagi, Kie Yoshida-Tanaka, Asuka Sasaki, Aya Abe, Satoe Ebihara, et al.

    Recent advances in gapmer antisense oligonucleotides (ASOs) have led to the regulatory approval of ASO therapeutics that target the liver and central nervous system. Efficient delivery of gapmer ASOs to muscle tissue will further broaden their therapeutic applications. Here, we evaluated the knockdown activity of lipid-conjugated DNA/RNA heteroduplex oligonucleotides (HDOs) in muscle tissue. Cholesterol-conjugated HDO (Chol-HDO) exhibited effective gene suppression in both cardiac and skeletal muscles, outperforming unconjugated ASO and cholesterol-conjugated ASO (Chol-ASO). Chol-HDO and Chol-ASO showed greater binding to low-density lipoprotein (LDL); however, while Chol-ASO also exhibited enhanced binding to other serum proteins, Chol-HDO displayed weaker nonspecific interactions. Mechanistically, Chol-HDO enhanced cellular uptake through an LDL receptor-mediated mechanism. Moreover, subcellular distribution analysis revealed that the duplex structure of Chol-HDO promoted efficient nuclear delivery. Regarding safety, intravenous injection of Chol-ASO induced thrombocytopenia, whereas Chol-HDO mitigated this effect at the same dose. Ex vivo platelet activation assays confirmed that platelet activation was significantly more suppressed by Chol-HDO treatment than by Chol-ASO. Taken together, these results underscore the therapeutic potential of HDOs for safe and effective knockdown in muscle tissue, and provide a novel platform for the clinical development of gapmer ASO therapy for muscular disorders.


  • Open Access

    Stage-specific roles of clonally expanded CD8+ T cells in regulating amyloid pathology in Alzheimer’s disease models

    by Masaki Ohyagi, Minako Ito, Mana Iizuka-Koga, Setsuko Mise-Omata, Akihiko Yoshimura

    Clonally expanded CD8+ T cells may contribute to Alzheimer’s disease (AD) pathology through interactions with brain-resident cells. However, the functional impact of AD-specific T cell receptor (TCR) clonotypes remains unclear. Here, we demonstrate that CD8+ T cells undergo clonal expansion in early-stage AD mouse models, AppNL-G-F and 5xFAD, and that their depletion reduces amyloid plaque accumulation. Expanded TCR-expressing CD8+ T cells preferentially infiltrate the brain, exacerbating plaque deposition. Moreover, brain-infiltrating CD8+ T cells impair microglial transition into disease-associated states, suppressing amyloid clearance via CCL5-CCR5 signaling. Pharmacological blockade of CCL5 attenuates amyloid deposition, whereas CCL5 administration aggravates pathology. Notably, T cell depletion at later disease stages exacerbates amyloid pathology, suggesting a temporal shift in their function. Early-stage CD8+ T cells exhibit cytotoxic and effector profiles, whereas late-stage cells acquire tissue-resident and exhausted phenotypes. This temporal switch—from pathogenic to protective roles—highlights the stage-specific contribution of CD8+ T cells to AD and their potential as therapeutic targets.


  • Open Access

    Legius syndrome mutations in the Ras-regulator SPRED1 abolish its membrane localization and potentially cause neurodegeneration

    by Yasuko Hirata, Hilde Brems, Seppe Van der Auweraer, Masaki Ohyagi, Mana Iizuka, Setsuko Mise-Omata, Minako Ito, Ludwine Messiaen, Seiya Mizuno, Satoru Takahashi, et al.


  • Open Access

    Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant

    by Setsuko Mise-Omata, Mari Ikeda, Masaru Takeshita, Yoshifumi Uwamino, Masatoshi Wakui, Tomoko Arai, Ayumi Yoshifuji, Kensaku Murano, Haruhiko Siomi, Kensuke Nakagawara, et al.

    Although the immunological memory produced by BNT162b2 vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been well studied and established, further information using different racial cohorts is necessary to understand the overall immunological response to vaccination. We evaluated memory B and T cell responses to the severe acute respiratory syndrome coronavirus 2 spike protein before and after the third booster using a Japanese cohort. Although the Ab titer against the spike receptor-binding domain (RBD) decreased significantly 8 mo after the second vaccination, the number of memory B cells continued to increase, whereas the number of memory T cells decreased slowly. Memory B and T cells from unvaccinated infected patients showed similar kinetics. After the third vaccination, the Ab titer increased to the level of the second vaccination, and memory B cells increased at significantly higher levels before the booster, whereas memory T cells recovered close to the second vaccination levels. In memory T cells, the frequency of CXCR5+CXCR3+CCR6− circulating follicular Th1 was positively correlated with RBD-specific Ab-secreting B cells. For the response to variant RBDs, although 60–80% of memory B cells could bind to the omicron RBD, their avidity was low, whereas memory T cells show an equal response to the omicron spike. Thus, the persistent presence of memory B and T cells will quickly upregulate Ab production and T cell responses after omicron strain infection, which prevents severe illness and death due to coronavirus disease 2019.


  • T cells in the brain inflammation

    by Akihiko Yoshimura, Masaki Ohyagi, Minako Ito


  • Open Access

    Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve

    by Hidetoshi Kaburagi, Tetsuya Nagata, Mitsuhiro Enomoto, Takashi Hirai, Masaki Ohyagi, Kensuke Ihara, Kie Yoshida-Tanaka, Satoe Ebihara, Ken Asada, Hiroyuki Yokoyama, et al.


  • Open Access

    Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides

    by Rieko Nishi, Masaki Ohyagi, Tetsuya Nagata, Yo Mabuchi, Takanori Yokota


  • Open Access

    DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo

    by Masaki Ohyagi, Tetsuya Nagata, Kensuke Ihara, Kie Yoshida-Tanaka, Rieko Nishi, Haruka Miyata, Aya Abe, Yo Mabuchi, Chihiro Akazawa, Takanori Yokota

    Manipulating lymphocyte functions with gene silencing approaches is promising for treating autoimmunity, inflammation, and cancer. Although oligonucleotide therapy has been proven to be successful in treating several conditions, efficient in vivo delivery of oligonucleotide to lymphocyte populations remains a challenge. Here, we demonstrate that intravenous injection of a heteroduplex oligonucleotide (HDO), comprised of an antisense oligonucleotide (ASO) and its complementary RNA conjugated to α-tocopherol, silences lymphocyte endogenous gene expression with higher potency, efficacy, and longer retention time than ASOs. Importantly, reduction of Itga4 by HDO ameliorates symptoms in both adoptive transfer and active experimental autoimmune encephalomyelitis models. Our findings reveal the advantages of HDO with enhanced gene knockdown effect and different delivery mechanisms compared with ASO. Thus, regulation of lymphocyte functions by HDO is a potential therapeutic option for immune-mediated diseases.


  • Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood–brain barrier and knock down genes in the rodent CNS

    by Tetsuya Nagata, Chrissa A. Dwyer, Kie Yoshida-Tanaka, Kensuke Ihara, Masaki Ohyagi, Hidetoshi Kaburagi, Haruka Miyata, Satoe Ebihara, Kotaro Yoshioka, Takashi Ishii, et al.

    Achieving regulation of endogenous gene expression in the central nervous system (CNS) with antisense oligonucleotides (ASOs) administered systemically would facilitate the development of ASO-based therapies for neurological diseases. We demonstrate that DNA/RNA heteroduplex oligonucleotides (HDOs) conjugated to cholesterol or α-tocopherol at the 5′ end of the RNA strand reach the CNS after subcutaneous or intravenous administration in mice and rats. The HDOs distribute throughout the brain, spinal cord and peripheral tissues and suppress the expression of four target genes by up to 90% in the CNS, whereas single-stranded ASOs conjugated to cholesterol have limited activity. Gene knockdown was observed in major CNS cell types and was greatest in neurons and microglial cells. Side effects, such as thrombocytopenia and focal brain necrosis, were limited by using subcutaneous delivery or by dividing intravenous injections. By crossing the blood–brain barrier more effectively, cholesterol-conjugated HDOs may overcome the limited efficacy of ASOs targeting the CNS without requiring intrathecal administration.